Among the pharmaceutical enterprises, Gannan Haixin has been listed on the new third board.
Gannan Haixin is listed on the new third board. In 2019, it will continue to grow well, successfully complete the "retreat from the city to the park", safely and orderly complete the relocation of the old factory and the commissioning of the new area, and complete the GMP certification of all preparation production lines. Xi'an Haixin will continue to improve its operation and management ability, focus on strengthening the production of raw materials and drugs, and lay the foundation for the development of the enterprise; Under the severe external market environment, Haixin pharmaceutical, on the one hand, adheres to the traditional business, strictly abides by the terminal channel, builds the marketing team, and at the same time, adheres to the innovation driven, innovation and change, actively responds to the challenges, goes against the trend, and keeps stable revenue; the phase III clinical trial of Haixin biological APDC project continues to advance, and as of the disclosure date of the annual report, the project has a total of 32 cases For example, during the reporting period, the company also carried out preliminary research on exploratory clinical trials; on the basis of rapid development in 2018, Suzhong Pharmaceutical Co., Ltd., which is a shareholder of the company, will continue to flourish in 2019, bringing better investment returns to the company.